Back to results
US 6,806,080 B2Granted
Hybrid vectors for gene therapy
AssigneesUniversity of Southern California, The Regent of the University of California
InventorsNoriyuki Kasahara, Collin Higo, Harris Soifer, Kohnosuke Mitani
Life of this patent
Estimating the term…
Abstract
The invention discloses hybrid vectors for delivering genes or other nucleic acids into mammalian cells. The hybrid vectors of the invention contain both a helper dependent adenoviral portion and a second portion derived from a transposon. Such vectors provide efficient transduction of quiescent cells and provide for stable integration of the gene to be delivered.
Claims14
A hybrid vector for genetic material delivery comprising a nucleic acid molecule comprising:
- (a) a helper-dependent adenoviral vector region comprising:
- (i) a first and a second adenoviral inverted terminal repeat, and
- (ii) an adenoviral packaging signal, wherein said adenoviral vector region lacks sequences encoding functional adenoviral genes necessary for replication or packaging;
- and
- (b) a non-LTR retrotransposon region comprising:
- (i) a first nucleic acid region encoding a non-LTR retrotransposon protein or proteins, and
- (ii) a promoter region comprising a 5′ untranslated region of a non-LTR retrotransposon operably linked to said first nucleic acid region.
4 more elements
Dependencies are inferred from the claim text.